|
Name |
Quinolactacin A1
|
| Molecular Formula | C16H18N2O2 | |
| IUPAC Name* |
(3R)-3-[(2S)-butan-2-yl]-4-methyl-2,3-dihydropyrrolo[3,4-b]quinoline-1,9-dione
|
|
| SMILES |
CC[C@H](C)[C@@H]1C2=C(C(=O)C3=CC=CC=C3N2C)C(=O)N1
|
|
| InChI |
InChI=1S/C16H18N2O2/c1-4-9(2)13-14-12(16(20)17-13)15(19)10-7-5-6-8-11(10)18(14)3/h5-9,13H,4H2,1-3H3,(H,17,20)/t9-,13+/m0/s1
|
|
| InChIKey |
FLHQAMWKNPOTDV-TVQRCGJNSA-N
|
|
| Synonyms |
Quinolactacin A1; (+)-Quinolactacin A1; 815576-68-2; (3R)-2,3-dihydro-4-methyl-3-[(1S)-1-methylpropyl]-1H-pyrrolo[3,4-b]quinoline-1,9(4H)-dione; HY-N7480A; ZINC14684867; CS-0136107; (3R)-3-[(2S)-butan-2-yl]-4-methyl-2,3-dihydropyrrolo[3,4-b]quinoline-1,9-dione
|
|
| CAS | NA | |
| PubChem CID | 26202199 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 270.33 | ALogp: | 2.5 |
| HBD: | 1 | HBA: | 3 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 49.4 | Aromatic Rings: | 3 |
| Heavy Atoms: | 20 | QED Weighted: | 0.911 |
| Caco-2 Permeability: | -4.741 | MDCK Permeability: | 0.00001850 |
| Pgp-inhibitor: | 0.049 | Pgp-substrate: | 0.879 |
| Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.01 |
| 30% Bioavailability (F30%): | 0.112 |
| Blood-Brain-Barrier Penetration (BBB): | 0.946 | Plasma Protein Binding (PPB): | 80.68% |
| Volume Distribution (VD): | 1.469 | Fu: | 10.49% |
| CYP1A2-inhibitor: | 0.918 | CYP1A2-substrate: | 0.824 |
| CYP2C19-inhibitor: | 0.411 | CYP2C19-substrate: | 0.809 |
| CYP2C9-inhibitor: | 0.497 | CYP2C9-substrate: | 0.534 |
| CYP2D6-inhibitor: | 0.173 | CYP2D6-substrate: | 0.276 |
| CYP3A4-inhibitor: | 0.531 | CYP3A4-substrate: | 0.212 |
| Clearance (CL): | 2.275 | Half-life (T1/2): | 0.115 |
| hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.217 |
| Drug-inuced Liver Injury (DILI): | 0.251 | AMES Toxicity: | 0.872 |
| Rat Oral Acute Toxicity: | 0.158 | Maximum Recommended Daily Dose: | 0.8 |
| Skin Sensitization: | 0.087 | Carcinogencity: | 0.889 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.196 |
| Respiratory Toxicity: | 0.352 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002158 | ![]() |
0.522 | D06GKN | ![]() |
0.356 | ||
| ENC004684 | ![]() |
0.430 | D0K7WK | ![]() |
0.356 | ||
| ENC004688 | ![]() |
0.425 | D05EPM | ![]() |
0.329 | ||
| ENC004691 | ![]() |
0.425 | D07RGW | ![]() |
0.320 | ||
| ENC004686 | ![]() |
0.423 | D08UMH | ![]() |
0.316 | ||
| ENC004693 | ![]() |
0.423 | D0J6WW | ![]() |
0.295 | ||
| ENC004267 | ![]() |
0.389 | D06IXT | ![]() |
0.295 | ||
| ENC002809 | ![]() |
0.379 | D06BYV | ![]() |
0.288 | ||
| ENC005470 | ![]() |
0.368 | D03GET | ![]() |
0.282 | ||
| ENC005998 | ![]() |
0.360 | D08EOD | ![]() |
0.280 | ||